144 related articles for article (PubMed ID: 23445368)
1. Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma.
Hourigan CS; Forde PM; Ambinder RF; Gladstone DE
Leuk Lymphoma; 2013 Nov; 54(11):2563-4. PubMed ID: 23445368
[No Abstract] [Full Text] [Related]
2. [Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].
Satou Y; Matsuoka M
Nihon Rinsho; 2004 Jul; 62(7):1363-7. PubMed ID: 15283157
[TBL] [Abstract][Full Text] [Related]
3. Response to bortezomib of a patient with scleromyxedema refractory to other therapies.
Migkou M; Gkotzamanidou M; Terpos E; Dimopoulos MA; Kastritis E
Leuk Res; 2011 Nov; 35(11):e209-11. PubMed ID: 21831425
[No Abstract] [Full Text] [Related]
4. [Clinical analysis of bortezomib combined with chemotherapy for one case of refractory acute lymphocytic leukemia].
Xu JJ; Hu XH; Shen YY
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):697-8. PubMed ID: 22339831
[No Abstract] [Full Text] [Related]
5. Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity.
Hu X; Xu J; Sun A; Shen Y; He G; Guo F
Leuk Lymphoma; 2011 Dec; 52(12):2393-5. PubMed ID: 21745166
[No Abstract] [Full Text] [Related]
6. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma.
Chaoui D; Bouallegue S; Arakelyan N; Genet P; Aljijakli A; Sutton L
Br J Haematol; 2014 Mar; 164(5):750-2. PubMed ID: 25136706
[No Abstract] [Full Text] [Related]
8. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
Younes A; Pro B; Fayad L
Blood; 2006 Feb; 107(4):1731-2. PubMed ID: 16461762
[No Abstract] [Full Text] [Related]
9. New developments with bortezomib in treating multiple myeloma.
Reddy GK
Clin Lymphoma; 2004 Mar; 4(4):215-6. PubMed ID: 15072611
[No Abstract] [Full Text] [Related]
10. Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
Kuroda J; Kobayashi T; Tsutsumi Y; Yamamoto M; Ohshiro M; Sasaki N; Shimura Y; Mizutani S; Nagoshi H; Kiyota M; Nakayama R; Uchiyama H; Matsumoto Y; Horiike S; Shimazaki C; Taniwaki M
Int J Hematol; 2010 Nov; 92(4):669-72. PubMed ID: 20978877
[No Abstract] [Full Text] [Related]
11. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib.
Grassinger J; Südhoff T; Andreesen R; Hennemann B
Ann Hematol; 2006 Feb; 85(2):132-3. PubMed ID: 16311736
[No Abstract] [Full Text] [Related]
12. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
Di Bella N; Taetle R; Kolibaba K; Boyd T; Raju R; Barrera D; Cochran EW; Dien PY; Lyons R; Schlegel PJ; Vukelja SJ; Boston J; Boehm KA; Wang Y; Asmar L
Blood; 2010 Jan; 115(3):475-80. PubMed ID: 19965689
[TBL] [Abstract][Full Text] [Related]
13. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation.
Mateos-Mazon J; Pérez-Simón JA; Lopez O; Hernández E; Etxebarria J; San Miguel JF
Haematologica; 2007 Sep; 92(9):1295-6. PubMed ID: 17768136
[TBL] [Abstract][Full Text] [Related]
14. Successful bone reconstruction after bortezomib therapy in a myeloma patient.
Tanaka T; Yamasaki R; Omura H; Hino N
Int J Hematol; 2011 Sep; 94(3):221. PubMed ID: 21861100
[No Abstract] [Full Text] [Related]
15. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
Beaven AW; Shea TC; Moore DT; Feldman T; Ivanova A; Ferraro M; Ford P; Smith J; Goy A
Leuk Lymphoma; 2012 Feb; 53(2):254-8. PubMed ID: 21812533
[TBL] [Abstract][Full Text] [Related]
16. Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis.
Dispenzieri A
Leukemia; 2014 Dec; 28(12):2273-5. PubMed ID: 25492370
[No Abstract] [Full Text] [Related]
17. Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Ribrag V; Tilly H; Casasnovas O; Bosly A; Bouabdallah R; Delarue R; Boue F; Bron D; Feugier P; Haioun C; Offner F; Coiffier B
Eur J Cancer; 2013 Mar; 49(4):904-10. PubMed ID: 23273434
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
Strauss SJ; Maharaj L; Hoare S; Johnson PW; Radford JA; Vinnecombe S; Millard L; Rohatiner A; Boral A; Trehu E; Schenkein D; Balkwill F; Joel SP; Lister TA
J Clin Oncol; 2006 May; 24(13):2105-12. PubMed ID: 16606971
[TBL] [Abstract][Full Text] [Related]
19. [Bortezomib].
Simons S; Scheulen ME; Jaehde U
Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
[No Abstract] [Full Text] [Related]
20. [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
Huang WR; Li R; Jing Y; Zhang YZ; Wu XX; Gao CJ; Bo J; Yu L; Wang QS; Da WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1146-50. PubMed ID: 17204182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
